Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company headquartered in Burnaby, British Columbia. The company develops therapeutic candidates targeting neurological and psychiatric disorders, with its most advanced program being Azetukalner, a selective Kv7 potassium channel opener currently in Phase 3 clinical trials. Azetukalner is being evaluated for focal onset seizures and primary generalized tonic-clonic seizures, as well as neuropsychiatric indications including major depressive disorder and bipolar depression.

The company also holds a license and collaboration agreement with Neurocrine Biosciences for NBI-921352, a Nav1.2/1.6 sodium channel inhibitor in Phase 1 trials for specific epilepsy types. This partnership represents a secondary revenue stream through potential milestone payments and royalties on future sales. The company's clinical-stage portfolio is primarily focused on rare and central nervous system disorders.

Xenon operates as a development-stage biopharmaceutical company without approved marketed products, generating revenue primarily through collaboration agreements rather than product sales. The company was incorporated in 1996 and maintains operations in Canada while conducting multinational clinical trials through its product development programs.